ferumoxytol or oral iron

Phase 3Small molecule

AAMAG Pharmaceuticals, Inc.

ferumoxytol or oral iron is one of 72 small molecule programs targeting Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

AnemiaPhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

ferumoxytol or oral iron

AAMAG Pharmaceuticals, Inc.

Phase 3

2 4

Vemlidy

Gilead

Preclinical

1 5

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

2 8

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

PROCRIT

WWim Janssens

Preclinical

1 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease2 trials

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

Completed·AAMAG Pharmaceuticals, Inc.·Phase 3·NCT00255437·304 enrolled

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

Completed·AAMAG Pharmaceuticals, Inc.·Phase 3·NCT00255424·304 enrolled

Anemia1 trial

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients

Completed·AAMAG Pharmaceuticals, Inc.·Phase 3·NCT00233597·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ferumoxytol or oral iron. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ferumoxytol or oral iron compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ferumoxytol or oral iron. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AMAG Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAMAG Pharmaceuticals, Inc.

ferumoxytol or oral iron

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease2 trials

Anemia1 trial

References

Drug Info

Quick Facts

Related News